Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

NIH Investigators Discover New Targets for Anti-Malarial Drugs

OCT 27, 2017 | CONTAGION® EDITORIAL STAFF
Armed with this new knowledge, the investigators were able to identify 3 experimental malaria drugs that may target plasmepsin X. The NIH mentioned one of these drugs, CWHM-117, which “has already been tested in a mouse model of malaria.” Knowing more about the role of plasmepsin X may help researchers to modify CWHM-117 to render it more effective. In addition, the NIH states that “parasites lacking the plasmepsins could potentially be used to screen candidate drugs to identify additional anti-malaria compounds.”

New antimalarial drugs can be a game-changer in the fight against this deadly disease. Recently, Jeremy Burrows, DPhil, MA, Vice President, Head of Discovery, Medicines for Malaria Venture, Switzerland, sat down with Contagion® to explain why.



The NIH study was conducted with funding provided by the National Institute of Allergy and Infectious Diseases, the National Heart, Lung, and Blood Institute, and the National Institute of General Medical Sciences.

The full study is published in the journal, Science.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.


FEATURED
We break down our top HIV news stories of 2017. Did you read them all?
x